Prospects for the targeted treatment research of TSHR and IGF-1R in Graves disease and Graves ophthalmopathy
10.3760/cma.j.cn321828-20190730-00153
- VernacularTitle:格雷夫斯病及格雷夫斯眼病靶向TSHR及IGF-1R治疗策略展望
- Author:
Wei ZHENG
1
;
Xuan WANG
;
Ning LI
;
Zhongying RUI
;
Jian TAN
;
Zhaowei MENG
;
Qiang JIA
;
Danyang SUN
;
Yang YU
Author Information
1. 天津医科大学总医院核医学科 300052
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2020;40(7):434-439
- CountryChina
- Language:Chinese
-
Abstract:
Anti-thyroid drug (ATD), radioactive iodine (RAI) and thyroidectomy are treatment options for Graves disease (GD). Treatment strategies for Graves ophthalmopathy (GO) patients include thyroid function control, oral or intravenous corticosteroids, orbital radiotherapy or orbital decompression surgery. However, current treatments for GD and GO are also less ideal because they target the signs and symptoms rather than the pathogenic mechanisms. The development of treatment strategies that targeting the thyroid-stimulating hormone receptor (TSHR) or insulin-like growth factor 1 receptor (IGF-1R) alone or in combination may yield effective and better tolerated treatments for GD and GO. This paper reviews the progress and limitations of the 2 methods.
